Consenso sobre las actuaciones a seguir durante la edad fértil, el embarazo, el posparto y la lactancia en pacientes con psoriasis

Belinchón, I.; Velasco, María; Ara‐Martín, Mariano; Armesto, Susana; Rodríguez, Ofelia Baniandrés; Pulido, Laura; García‐Bustínduy, M.; Martínez-López, Juan Antonio; Sánchez, Núria Martínez; Ferriols, Amparo Pérez; Pascual, Eliseo; Díaz, Raquel Rivera; Ruiz‐Villaverde, Ricardo; Ferrer, Rosa Taberner; Villa, Asunción Vicente; Carrascosa, J.M.

doi:10.1016/j.ad.2020.10.002

Cited by 14 publications

(5 citation statements)

References 99 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Regarding topical agents, tazarotene is the only contraindicated drug [72]. Topical corticosteroids may be prescribed during breastfeeding [73].…”

Section: Psoriasis and Breastfeedingmentioning

confidence: 99%

“…Calcineurin inhibitors, calcipotriol, and anthralin can be used in minimal doses and for a limited time, after analyzing the benefits and risks of their administration [72]. These topical medications must not be applied to the nipple and areola [72]. During pregnancy, narrowband UVB can be used safely during breastfeeding [73].…”

Section: Psoriasis and Breastfeedingmentioning

confidence: 99%

Section: Psoriasis and Breastfeedingmentioning

confidence: 99%

“…Experts recommend the use of certolizumab pegol during breastfeeding, and, in addition, some consider it to be a first-line therapy for moderate to severe psoriasis in lactating women [53,78]. Information on the use of other biologic agents during breastfeeding is limited [72].…”

Section: Psoriasis and Breastfeedingmentioning

confidence: 99%

See 3 more Smart Citations

Oversight and Management of Women with Psoriasis in Childbearing Age

et al. 2022

View full text Add to dashboard Cite

Psoriasis is a complex disease with many associated comorbidities, all of which have a negative impact on a patient’s personal, social, and sexual life. There are some unique considerations in the effects of this disease among women. The average age of diagnosis in women with psoriasis is 28 years, and this onset corresponds to the fertile life of women. There is conflicting information about the effects of psoriasis on female fertility. Some studies suggest that this condition’s associated comorbidities, personal behaviors, and reduced ovarian reserve, especially due to chronic inflammation, affect women’s fertility. Another possible reason women with psoriasis are less likely to become pregnant is that their sexual intercourse frequency decreases after the condition’s onset. The available information on the effects of pregnancy on women with psoriasis is limited. According to current evidence, most women will experience an improvement in their skin condition. Studies show that patients with moderate-to-severe psoriasis are more prone to experience pregnancy complications. The management of pregnant and lactating women with psoriasis is also difficult, as the safety profile of commonly used drugs in patients with psoriasis is not entirely known.

show abstract

“…Regarding topical agents, tazarotene is the only contraindicated drug [72]. Topical corticosteroids may be prescribed during breastfeeding [73].…”

Section: Psoriasis and Breastfeedingmentioning

confidence: 99%

Section: Psoriasis and Breastfeedingmentioning

confidence: 99%

Section: Psoriasis and Breastfeedingmentioning

confidence: 99%

Section: Psoriasis and Breastfeedingmentioning

confidence: 99%

See 2 more Smart Citations

Oversight and Management of Women with Psoriasis in Childbearing Age

et al. 2022

View full text Add to dashboard Cite

show abstract

“…The amounts of cyclosporine transferred to breast milk vary from case to case but tend to be reduced. However, it is recommended to avoid the use of cyclosporine during breastfeeding [ 121 ]. Regarding the use of biological agents, certolizumab pegol is excreted in small amounts in breast milk and is considered to be digested in the infant’s gastrointestinal tract.…”

Section: Psoriasis and Lactationmentioning

confidence: 99%

Therapy of PsO in Special Subsets of Patients

et al. 2022

View full text Add to dashboard Cite

Psoriasis is a chronic, inflammatory skin disease that may occur at any age, with a bimodal peak of incidence around the age of 16–20 years of age (early onset) and 57–60 years (late-onset). It is estimated that roughly 70% of patients develop the disease before the age of 40, which coincides with the reproductive years. Moreover, psoriasis is a chronic disease, meaning that, with increased life-duration expectancy, the number of patients affected with psoriasis aged over 65 years is going to increase and represent a big therapeutic challenge. Actually, no specific drug recommendation is available, based only on the age of the patients, while therapeutic prescription should take into account that elderly patients have more comorbidities than younger patients, with polypharmacy and an increased risk of drug interactions. Women with psoriasis are more likely to report a worse influence of the disease on their quality of life, and they are more susceptible to the development of depression. Furthermore, pregnancy and lactation represent a major contraindication to several systemic agents, and only a few studies exist providing the safety of certain drugs during these periods of life of a woman, such as certolizumab pegol. In this paper, we discuss systemic therapeutic strategies, including conventional and biological therapies, in a special subset of patients affected with moderate-to-severe psoriasis focusing on elderly patients and on female patients in fertile age, pregnancy, and lactation.

show abstract